Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30
Benzinga Newsdesk 4 months ago
NewsPrice TargetInitiationAnalyst Ratings
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $30.
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $30.